How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/granulomatosis-with-polyangiitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Granulomatosis with polyangiitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Granulomatosis with polyangiitis (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Granulomatosis with polyangiitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Tavneos	AVACOPAN	Chemocentryx	Complement 5a Receptor Antagonist [EPC]	C5a anaphylatoxin chemotactic receptor 1	2021-01-01
Mabthera	rituxan	Roche	CD20-directed Cytolytic Antibody	B-lymphocyte antigen CD20	1997-01-01
Mabthera	Rituximab-Pvvr	Roche	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Mabthera	rituximab	Roche	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	1997-01-01
Tavneos	CCX168	Chemocentryx	Complement 5a Receptor Antagonist	C5a anaphylatoxin chemotactic receptor 1	2021-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 3 drugs in Granulomatosis with polyangiitis
Chemocentryx · 2 drugs in Granulomatosis with polyangiitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Granulomatosis with polyangiitis:

Cite this brief

Drug Landscape (2026). Granulomatosis with polyangiitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/granulomatosis-with-polyangiitis. Accessed 2026-06-10.

Granulomatosis with polyangiitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing